Premium
Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
Author(s) -
Jordan Allan,
Hadfield John A.,
Lawrence Nicholas J.,
McGown Alan T.
Publication year - 1998
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u
Subject(s) - vinca , tubulin , vinblastine , paclitaxel , colchicine , microtubule , vinca alkaloid , antimitotic agent , mitosis , biology , alkaloid , spindle apparatus , vincristine , pharmacology , binding site , chemistry , biochemistry , microbiology and biotechnology , cell division , stereochemistry , cell , cancer , genetics , chemotherapy , cyclophosphamide
Tubulin is the biochemical target for several clinically used anticancer drugs, including paclitaxel and the vinca alkaloids vincristine and vinblastine. This review describes both the natural and synthetic agents which are known to interact with tubulin. Syntheses of the more complex agents are referenced and the potential clinical use of the compounds is discussed. This review describes the biochemistry of tubulin, microtubules, and the mitotic spindle. The agents are discussed in relation to the type of binding site on the protein with which they interact. These are the colchicine, vinca alkaloid, rhizoxin/maytansine, and tubulin sulfhydryl binding sites. Also included are the agents which either bind at other sites or unknown sites on tubulin. The literature is reviewed up to October 1997. © 1998 John Wiley & Sons, Inc., Med Res Rev, 18, No. 4, 259–296, 1998.